Szlosarek, P. W. et al. JAMA Oncol 3, 58-66 (2017).
Archives: Publications
Publications
Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial
Krug, L. M. et al. Lancet Oncol 16, 447-456 (2015).
Progression free survival rate at 9 and 18 weeks predict overall survival in patients with malignant pleural mesothelioma: an individual patient pooled analysis of 10 European Organisation for Research and Treatment of Cancer Lung Cancer Group studies and an independent study validation
Hasan, B. et al. Eur J Cancer 50, 2771-2782 (2014).